Lyell Immunopharma, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Lyell Immunopharma, Inc. (LYEL) had Debt Securities, Available-for-sale, Unrealized Loss Position of $621.60 million as of 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Notes › Investments
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2022-08-04
- 2022-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $621.60M.
- 2022-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $680.10M.
- 2021-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $602.90M.
- 2020-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $132.60M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2022-06-30 | $621.60M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $680.10M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $602.90M 10-Q · filed 2022-08-04 |
| 2020-12-31 | $132.60M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |